Results 161 to 170 of about 571,340 (296)
Comprehensive Review of Anesthetic Strategies for Patients With Neurodegenerative Diseases. [PDF]
Grabarczyk Ł.
europepmc +1 more source
Predictive Ability of Plasma p‐tau217 for β‐Amyloid Status: A Prospective Multicenter Study
ABSTRACT Objective Plasma tau phosphorylated at threonine 217 (p‐tau217) measured with fully automated platforms has shown high accuracy for Alzheimer's disease (AD) diagnosis, but real‐world multicenter data remain limited. We aimed to validate the diagnostic performance of p‐tau217 for identifying AD pathology in a real‐world multicenter cohort ...
Miquel Massons +33 more
wiley +1 more source
Implant Therapy in Patients With Neurodegenerative Diseases-A Scoping Review. [PDF]
David L +5 more
europepmc +1 more source
A Case of Cerebral Cortical Encephalitis
Annals of Clinical and Translational Neurology, EarlyView.
Sixiao Liu, Kunqian Ji, Wei Wu, Wei Li
wiley +1 more source
ABSTRACT Background Cognitive impairment is a common non‐motor symptom in Multiple Sclerosis (MS), negatively affecting autonomy and Quality of Life (QoL). Innovative rehabilitation strategies, such as semi‐immersive virtual reality (VR) and computerized cognitive training (CCT), may offer advantages over traditional cognitive rehabilitation (TCR ...
Maria Grazia Maggio +8 more
wiley +1 more source
Could targeting viruses be a new hope against neurodegenerative diseases? [PDF]
Danzer KM, Sparrer KM.
europepmc +1 more source
Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS
ABSTRACT Objective Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels are believed to reflect mainly acute and chronic disease processes in multiple sclerosis (MS), respectively. In this study, we investigated whether dimethyl fumarate (DMF) and rituximab (RTX) differentially affect these biomarkers.
F. Shawket +14 more
wiley +1 more source
Extracellular vesicle-based therapies for neurodegenerative diseases. [PDF]
Hu G +4 more
europepmc +1 more source
Rev-erbs and glia—implications for neurodegenerative diseases [PDF]
Dimitry, Julie M. +2 more
core +1 more source
Safety and Tolerability of Givinostat: Evidence From Real‐World and Clinical Practice
ABSTRACT Objective The aim of our study was to establish the prevalence of adverse events in a real‐world setting in boys living with Duchenne muscular dystrophy (DMD) treated with givinostat as part of an Expanded Access Program (EAP) in Italy. Methods The cohort included 90 ambulant boys, with age when treatment started between 6 and 23 years (mean ...
Marika Pane +19 more
wiley +1 more source

